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A versatile assay to 
determine bacterial and 
host factors contributing to 
opsonophagocytotic killing in 
hirudin-anticoagulated whole 
blood
Erika van der Maten1, Marien I. de Jonge1, Ronald de Groot1, Michiel van der Flier1,2 & 
Jeroen D. Langereis1
Most bacteria entering the bloodstream will be eliminated through complement activation on the 
bacterial surface and opsonophagocytosis. However, when these protective innate immune systems 
do not work optimally, or when bacteria are equipped with immune evasion mechanisms that prevent 
killing, this can lead to serious infections such as bacteremia and meningitis, which is associated with 
high morbidity and mortality. In order to study the complement evasion mechanisms of bacteria 
and the capacity of human blood to opsonize and kill bacteria, we developed a versatile whole blood 
killing assay wherein both phagocyte function and complement activity can easily be monitored and 
modulated. In this assay we use a selective thrombin inhibitor hirudin to fully preserve complement 
activity of whole blood. This assay allows controlled analysis of the requirements for active complement 
by replacing or heat-inactivating plasma, phagocyte function and bacterial immune evasion 
mechanisms that contribute to survival in human blood.
Blood is normally sterile, but in cases when epithelial barriers are compromised and the immune system is not 
optimally equipped to fight pathogens, bacteria can be present in the blood, which is called bacteremia. Bacteria 
have evolved various mechanisms that prevent opsonophagocytosis, contributing to their ability to colonize their 
host, but also occasionally resulting in severe infections. Overall, Gram-positive bacteria are protected from 
complement-mediated lysis by the presence of a thick outer cell wall consisting of peptidoglycan, which prevents 
the bacterial membrane from lysis by the pore-forming membrane attack complex1. Conversely, Gram-negative 
bacteria, which are characterized by an outer membrane surrounding the bacterial cell wall, are vulnerable to 
complement-mediated killing due to assembly and insertion of the membrane attack complex on the bacte-
rial surface2. Several bacterial species express a polysaccharide capsule, that protects them from recognition by 
opsonizing antibodies and in Gram-negative bacteria such as Haemophilus influenzae from insertion of the mem-
brane attack complex3.
Besides a protective capsule, which can be found on both Gram-positive and Gram-negative bacteria, many 
invasive bacteria are able to hijack human complement regulatory proteins, thereby decreasing complement 
activation on their bacterial surface. For instance, Streptococcus pneumoniae, H. influenzae, Escherichia coli and 
Neisseria meningitidis are able to bind human factor H4–7, which decreases alternative complement activation and 
thereby reduces C3 opsonization.
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In order to study the complement evasion mechanisms of bacteria, or the capacity of complement to opsonize 
and kill bacteria, most in vitro studies performed to date are using serum, plasma or baby rabbit complement 
containing active complement for complement opsonization. For opsonophagocytosis, isolated phagocytes or 
phagocyte-like cell lines such as HL-60 are used8–11. However, this is by no means representative to the real live 
situation in whole blood. For instance, the isolation of neutrophils leads to priming, which affects the ability of 
the neutrophils to form reactive oxygen species and changes their responses to cytokines12. In addition, serum 
has altered levels of coagulation proteins compared to plasma in whole blood. An example is plasminogen13, 
which can bind to the bacterial surface of S. pneumoniae and is involved in bacterial virulence14,15. Another 
example is fibrinogen, shown to bind to Streptococcus pyogenes M protein, which decreases C3b deposition and 
opsonophagocytosis16,17.
To circumvent these limitations in order to study complement-mediated opsonophagocytosis of bacteria, we 
explored the possibility to use whole blood directly after venous puncture for use in opsonophagocytosis assays. 
Here, we describe a versatile and easy to perform whole blood killing assay in which both phagocyte function and 
complement activity can be monitored and modulated. We used a selective thrombin inhibitor hirudin, which 
preserved complement activity of whole blood, in contrast to lithium heparin, sodium heparin, EDTA or sodium 
citrate.
Material and Methods
Ethics statement. After informed consent, a venous blood specimen was collected from the median cubital 
vein of healthy volunteers (age, 20–40 years; both males and females). Collection of blood was approved by the 
Ethics Committee of the Radboud University, Nijmegen, the Netherlands and experiments were carried out in 
accordance with local guidelines and regulations and complies with the Declaration of Helsinki and the Good 
Clinical Practice guidelines.
Bacterial growth conditions. Streptococcus pneumoniae strain TIGR418, Streptococcus pneumoniae strain 
TIGR4Δ pspC19, Klebsiella pneumoniae RUMC-KP01 (Clinical isolate Medical Microbiology, Radboud UMC 
Nijmegen, the Netherlands), Staphylococcus aureus strain NCTC 8178 (National Collection of Type Cultures), 
Escherichia coli BL21 DE3 (Agilent), Neisseria meningitidis serogroup B strain H44/6720, Pseudomonas aerugi-
nosa ATCC15692 (American Type Culture Collection), H. influenzae type A strain ATCC 9006 (American Type 
Culture Collection), H. influenzae type B strain ATCC 10211 (American Type Culture Collection), non-typeable 
H. influenzae (NTHi) strain R28663, NTHi strain 365521 and NTHi strain 11P6H22 were used in this study. H. 
influenzae was grown under shaking conditions at 37 °C in brain heart infusion (BHI) broth (Becton Dickinson) 
supplemented with 10 μ g/mL haemin (Sigma-Aldrich) μ g/mL β -nicotinamide adenine dinucleotide (Merck) 
(sBHI). S. pneumoniae was grown under static conditions at 37 °C with 5% CO2 in Todd-Hewitt broth supple-
mented with 5 g/L yeast extract. N. meningitidis was grown on blood agar plates and collected directly from over-
night plates. K. pneumoniae, S. aureus, E. coli and P. aeruginosa were grown under shaking conditions at 37 °C in 
Luria-Bertani (LB) broth.
IgG, IgM and C3 opsonization assays. Blood for serum collection was collected in SST II Advance tubes 
(BD, Ref. 367953). Tubes were inverted after blood was drawn, incubated for 15 minutes at room temperature to 
clot, centrifuged with 3000 × g for 15 min at room temperature and serum was stored in small aliquots at − 80 °C.
Blood for plasma preparation was collected in K2E (EDTA) tubes (BD ref. 367864), Trisodium citrate 
tubes (BD ref. 363047), Sodium heparin tubes (BD ref. 367869), Lithium heparin tubes (BD Ref. 368496) or 
S-Monovette r-Hirudin tubes (Sarstedt, ref. 04.1944.001). Tubes were inverted after blood was drawn, centrifuged 
with 3000 × g for 15 min at 4 °C and plasma was stored in small aliquots at − 80 °C.
For human IgG, human IgM and human C3 binding, bacteria (1.10E7 in 100 μ L) were incubated with 10% 
plasma or serum in Hank’s Balanced Salt Solution (HBSS) without phenol red containing Ca2+/Mg2++ 0.1% 
gelatin (HBSS3+ ) for 30 min at 37 °C. Bacteria were washed and incubated with 1:500 diluted FITC-labelled 
poly-clonal goat anti-human C3 (MP biomedicals), 1:100 diluted FITC-labelled Fc-specific goat anti-human IgG 
(Sigma-Aldrich) or 1:100 diluted FITC-labelled μ -chain-specific goat anti-human IgM (Sigma-Aldrich) in PBS 
with 2% BSA for 30 min at 4 °C. Bacteria were washed and fixed for 20 min with 2% paraformaldehyde. Bacteria 
were taken up in PBS for flow cytometry.
Whole blood killing assay. After informed consent was obtained, a venous blood specimen was collected 
from the median cubital vein of healthy volunteers (age, 20–40 years; both males and females) into S-Monovette 
r-Hirudin tubes (Sarstedt). Blood was kept at room temperature on a roller bench until used.
For the whole blood killing assay, 100 μ L of hirudin-anticoagulated blood was added per well in a 96-well 
plate. Bacterial suspensions in PBS, containing 1.10E5 colony forming units (CFU), were added in a maximum 
volume of 5 μ L and immediately mixed with the blood. The 96-well plate was incubated for the indicated time at 
37 °C under continuous shaking. The number of bacterial CFU was determined at start and after incubation by 
plating serial 10-fold dilutions. The percentage of bacteria that survived was calculated.
For plasma inactivation, 100 μ L of hirudin-anticoagulated blood was added per well in a 96-well plate and 
centrifuged at 1000 × g for 5 min. Plasma was removed and heat-inactivated for 20 min at 56 °C. Blood cells were 
washed by adding 100 μ L PBS and centrifuged with 1000 × g for 5 min. PBS was removed and heat-inactivated 
plasma was mixed with the pelleted cells and used for the killing assay. To examine the effect of plasma alone 
on bacterial clearance, 200 μ L hirudin-anticoagulated blood was centrifuged 1 min at 16.000 × g and 100 μ L 
plasma was used for the killing assay in the absence of blood cells. For 50%, 25% and 10% active plasma, 50 μ L, 
25 μ L and 10 μ L active plasma was mixed with 50 μ L, 75 μ L and 90 μ L heat-inactivated plasma, respectively, 
and was mixed with the pelleted blood cells and used for the killing assay. For plasma replacement, 100 μ L 
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of hirudin-anticoagulated blood was added per well in a 96-well plate and centrifuged at 1000 × g for 5 min. 
Plasma was removed and cells were washed by adding 100 uL PBS and centrifuged at 1000 × g for 5 min. PBS was 
removed and pooled hirudin-anticoagulated plasma was mixed with the pelleted cells and used for the killing 
assay. For C6-depleted serum (CompTech) and C6-deficient patient serum23, serum was diluted in PBS to 10%. 
Reconstitution of C6 was performed by supplementing 6.4 μ g/mL purified C6 (CompTech) in 10% serum because 
manufacturer’s product description states full reconstitution of serum was achieved with 64 μ g/mL.
Inhibitor cytochalysin D (cyto D) (Sigma-Aldrich), anti-complement receptor 3 (CR3) subunit CD11b anti-
body clone 44a (α -CD11b) (Gift from Prof. Leo Koenderman), 4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich), 
factor H (FH) (CompTech) or an equal volume of PBS were added to the hirudin-anticoagulated blood before 
adding the bacteria.
Phagocytosis of CFSE-loaded S. pneumoniae. S. pneumoniae was grown in Todd-Hewitt broth sup-
plemented with 5 g/L yeast extract to OD620 = 0.2, washed with PBS and labelled with carboxyfluorescein suc-
cinimidyl ester (CFSE) (Sigma-Aldrich) as previously described24. Five microliter (~1.106 CFU) CFSE-labelled 
bacteria were added to 100 uL hirudin-anticoagulated whole blood and incubated for 30 min. Red blood cells 
were lysed in ice-cold NH4Cl solution (8.3 g/L NH4Cl, 1 g/L KHCO3 and 37 mg/L EDTA) and washed once with 
ice-cold NH4Cl solution followed by a wash with PBS. Cells were stained with 1:200 diluted Alexa647-labelled 
α -CD16 (BD biosciences), 1:50 diluted V500-labelled α -CD3 (BD biosciences), 1:50 diluted PE-Cy7-labelled 
α -CD14 (Biolegend), 1:100 diluted BV421-labelled α -CD66b (BD biosciences) for 15 min. at room temperature. 
Cells were washed with PBS and analyzed by flow cytometry using a FACS LSR II (BD Biosciences). Data were 
analyzed using FlowJo v10.1.
Results and Discussion
Hirudin-anticoagulated blood is optimal for complement preservation. We used Streptococcus 
pneumoniae as model organism to set-up a whole blood killing assay because this bacterium is causing bacteremia 
in immune competent individuals25,26. In order to survive in blood, this bacterium has developed various mecha-
nisms that inhibit recognition by the immune system27. For efficient opsonophagocytic killing, C3b opsonization 
of the bacterial surface of S. pneumoniae is required28. To determine which anticoagulants preserved complement 
C3b opsonization capacity, we determined IgG, IgM and C3 binding to the bacterial surface of S. pneumoniae 
after 30 minutes with 10% human serum or 10% human plasma anticoagulated with hirudin, lithium heparin, 
sodium heparin, EDTA or sodium citrate.
Binding of IgG to the bacterial surface of S. pneumoniae incubated with 10% hirudin or EDTA anticoagulated 
human plasma was slightly increased compared to 10% human serum, whereas no significant differences for 
IgM were observed. More striking were the differences in C3 opsonization. Here, hirudin anticoagulated plasma 
showed the highest C3 opsonization of S. pneumoniae, whereas all other anticoagulants showed a significant 
decrease in C3 opsonization. Complement activity was preserved for at least 2 hours when blood was kept at room 
temperature (Fig. 1D). From these data, we conclude that hirudin anticoagulated plasma is superior in preserving 
complement activity.
Previously, Ison et al. determined killing of Neisseria meningitidis in citrate and heparin-anticoagulated 
whole blood29. In this study, heparin-anticoagulated whole blood was superior in killing N. meningitidis sero-
group A compared to citrate-anticoagulated whole blood. In subsequent experiments, the same group compared 
this whole blood killing assay to serum bactericidal assay with blood from vaccinated children and consistently 
showed increased sensitivity for the whole blood killing assay30,31. Also, they showed a reduction of survival 
of N. meningitidis in the whole blood killing assay with increasing age of patients32. Whole blood killing of 
N. meningitidis has also been performed with hirudin-anticoagulated whole blood. Welsch et al. showed efficient 
killing of N. meningitidis serogroup B with whole blood from adults33. A slightly modified whole blood killing 
assay, with 25% heat-inactivated serum, showed increased killing with post-immunization serum compared to 
pre-immunization serum34. Comparisons in whole blood killing between huridin and other anticoagulants have 
not been studied previously.
The differences in complement activity preservation can largely be explained by the function of the different 
anticoagulants. Lithium heparin and sodium heparin induce a conformational change of antithrombin III to 
accelerate the inhibition of thrombin and factor Xa, thus preventing thrombin activation and the generation of 
fibrin. However, heparin is known to bind different proteins in the complement cascade35, as well as calcium and 
magnesium ions36, thereby affecting complement activity. Sodium citrate prevents blood from clotting through 
chelation of calcium ions by forming calcium citrate and EDTA scavenges bi-valent cations, such as calcium and 
magnesium, both are also required for complement activation. In contrast, hirudin (also known as lepirudin) is a 
highly specific thrombin inhibitor that does not interfere with complement activation37.
Hirudin has previously also been used in whole blood stimulation assays33,38–40. This enables to determine the 
contribution of cross-talk between complement and other factors such as cytokine release38, oxidative burst40 and 
phagocytosis39.
Even though thrombin is not directly involved in complement activation, there are some reports where it has 
shown to modulate complement activity. For instance, in C3− /− mice, thrombin was overexpressed and showed 
to cleave C5 into C5a and C5b41. In these studies, hirudin reduced acute lung inflammatory injury in C3− /− 
mice, but had no effect in C3+ /+ , indicating that thrombin-mediated cleavage of C5 only contributed to acute 
lung inflammatory injury when C3 is absent.
Whole blood killing assay. Many bacterial pathogens such as S. pneumoniae, Staphylococcus aureus, 
Klebsiella pneumoniae N. meningitidis and H. influenzae frequently cause invasive disease, including sepsis42–44. 
When present in the blood, bacteria need to withstand the bactericidal activity of the complement system, and 
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phagocytosis by peripheral blood neutrophils. We used hirudin anticoagulated blood to determine the survival 
of invasive bacterial pathogens in blood. For these experiments, we used S. pneumoniae strain TIGR4, originally 
isolated from the blood of a 30-year-old male18,45.
The whole blood killing assay is an easy-to-use opsonophagocytic assay to determine survival of bacterial 
pathogens in blood. Bacteria are added to 100 μ L hirudin anticoagulated blood in a 96-wells round bottom plate 
and incubated at 37 °C while shaking to prevent sedimentation. Different inoculums (103–105 CFU/100 μ L blood) 
were tested and all showed a decrease in CFU counts over time (data not shown). For subsequent experiments, 
105 CFU/100 μ L blood were used.
We determined killing of S. pneumoniae in whole blood and observed significant killing already after 1 hour, 
which increased further in time (Fig. 2A). In order to determine the role of complement activity and phago-
cyte function, we performed the whole blood killing assay with either heat-inactivated plasma (see Material and 
Methods section for procedure) or with only plasma containing active complement. Whereas S. pneumoniae was 
killed in blood, no killing was observed with plasma only, indicating that phagocytes are required for efficient 
killing (Fig. 2B). When heat-inactivated plasma was mixed with blood cells, S. pneumoniae was able to grow very 
rapidly. This indicates that active complement is required for effective opsonophagocytosis as well, but also shows 
that whole blood contains sufficient nutrients for fastidious growth. The contribution of active complement in 
S. pneumoniae opsonophagocytosis is known for a long time46–48, and our results are consistent with these studies.
We determined whole blood killing after 1 hour for different pathogens that cause bacteremia42–44. Survival 
of S. pneumoniae strain TIGR4 was 20%. Similar survival was found for K. pneumoniae (16%) and P. aerug-
inosa (7%), whereas survival for S. aureus (85%) or H. influenzae serotype B (41%) were higher. Survival of 
H. influenzae serotype A (2%), E. coli (0.03%) and N. meningitidis (0.1%) was much lower. Survival of NTHi 
was strain dependent, 9% for R2886, but only 0.2% and 0.3% for strains 3655 and 11P6H, respectively. These 
strain-dependent differences in survival are probably due to variance in complement resistance since we have 
Figure 1. Plasma and serum IgG, IgM, C3 opsonization of S. pneumoniae. Bacteria (1.10E7) were incubated 
for 30 minutes in HBSS3+ containing 10% plasma anticoagulated with hirudin, lithium heparin, sodium 
heparin, EDTA or sodium citrate or serum from the same donor and binding of (A) IgG, (B) IgM, and (C) C3 
was determined by flow cytometry (n = 3). One-way analysis of variance (ANOVA) with Dunnett’s Multiple 
Comparison Test was used for statistical analysis. * p < 0.05, ** p < 0.01. (D) Hirudin anticoagulated blood was 
immediately (0 h) or after 2 hours rolling on a roller mixer (2 h) centrifuged and plasma was stored. Bacteria 
(1.10E7) were incubated for 30 minutes in HBSS3+ containing 10% of the plasma that was immediately or after 
2 hours stored, and binding C3 was determined by flow cytometry (n = 3). A one-tailed student t-test was used 
for statistical analysis. NS = not significant.
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previously shown that survival in pooled human serum was much lower for NTHi strains 3655 and 11P6H as 
compared to strain R28664.
In order to compare complement-mediated killing and opsonophagocytic-dependent killing for Gram 
negative and Gram positive bacteria, we determined survival of S. pneumoniae and NTHi strain 3655 with 
heat-inactivated plasma, plasma and whole blood. Both plasma and whole blood showed significant killing of 
NTHi strain 3655, whereas this was only the case with whole blood for S. pneumoniae (Fig. 2D). These data 
clearly indicate that killing of Gram negative, unencapsulated, NTHi strain 3655 was largely dependent on 
complement-mediated killing, whereas killing of S. pneumoniae was dependent on complement activation and 
opsonophagocytosis.
Modulation of bacterial, cellular and humoral factors contributing to whole blood killing. With 
this whole blood killing assay, bacterial factors as well as host cellular and humoral factors can be modulated to 
determine their contribution to opsonophagocytic killing. For instance, blocking complement receptor 3 (CR3) 
with α -CD11b antibody 44a decreased killing of S. pneumoniae (Fig. 3A), indicating that recognition of C3b on 
the bacterial surface by phagocytes contributes to killing. The contribution of the CR3 in opsonophagocytosis is 
S. pneumoniae by neutrophils and macrophages is widely investigating49–51, and our results are consistent with 
these studies.
In addition, treatment of blood with cytochalysin D, an inhibitor for actin polymerization, also decreased 
killing of S. pneumoniae (Fig. 3A), indicating that killing was dependent on phagocytosis.
Recently, Corriden et al. showed that tamoxifen augmented neutrophil-mediated killing of S. aureus, E. coli 
and Pseudomonas aeruginosa through enhancing several pro-inflammatory pathways in human neutrophils, 
including chemotaxis, phagocytosis and neutrophil extracellular trap (NET) formation52. Here, we show that 
adding 10 μ M 4-hydroxytamoxifen significantly augmented killing of S. pneumoniae in whole blood (Fig. 3B).
Killing of S. pneumoniae, but also other pathogens, is affected by the presence of opsonizing antibodies and the 
overall complement activity. To determine the role of complement activity, we used whole blood of which plasma 
was removed by centrifugation and replaced with 50%, 25% or 10% plasma containing active complement (see 
Material and Methods section for procedure). Replacement of the total amount of active plasma with 50% active 
plasma clearly decreased the killing capacity, which was even more apparent for 25% and 10% active plasma 
(Fig. 3C), indicating that decreasing the level of active complement reduces the capacity to clear S. pneumoniae 
from blood in a dose dependent manner.
Figure 2. Phagocytes and active complement are required for efficient opsonophagocytic killing of S. 
pneumoniae in whole blood. (A) Bacterial survival in hirudin anticoagulated whole blood was determined after 
1, 2 and 4 hours incubation (n = 3). One-way analysis of variance (ANOVA) with Dunnett’s Multiple Comparison 
Test was used for statistical analysis. *** p < 0.001. (B) Bacterial survival in whole blood, blood with heat-
inactivated plasma and plasma only was determined after 1, 2 and 4 hours incubation (n = 7). (C) Killing in hirudin 
anticoagulated whole blood of S. pneumoniae, S. aureus, K. pneumoniae, P. aeruginosa, E. coli, N meningitidis 
and H. influenzae were determined after 1 hour incubation (n = 3). Killing of S. pneumoniae and non-typeable 
H. influenzae influenzae (NTHi) strain 3655 was determined with heat-inactivated (HI) hirudin plasma, hirudin 
plasma and hirudin anticoagulated whole blood after 1 hour incubation (n = 2).
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Previously, we have used the whole blood killing assay to assess the contribution of human factor H in con-
trolling complement activity and killing of S. pneumoniae by replacing plasma with factor H-depleted serum and 
supplementation with different concentrations of purified human factor H. In this assay, we showed that increas-
ing human factor H to blood increased survival of S. pneumoniae, whereas decreasing factor H levels increased 
killing53. Adding 100 μ g/mL factor H to whole blood decreased killing of S. pneumoniae significantly (Fig. 3D), 
which is in accordance with the findings that higher factor H levels decreased bacterial killing53. Binding of factor 
H to the bacterial surface was shown to protect many bacteria from complement-mediated opsonization4,5,7,54–58. 
Pneumococcal surface protein C (PspC) of S. pneumoniae is known to bind human factor H. In order to deter-
mine the role for factor H binding in whole blood killing we determined survival of a Δ pspC mutant and found 
that this mutant, as expected, had a decreased survival in whole blood (Fig. 3E). Overall, this demonstrates several 
possibilities in studying functions of complement in bacterial clearance using the whole blood killing assay.
While performing our whole blood killing experiments, we observed large inter-patient differences in S. pneu-
moniae survival (% survival 0.03–2.00) (Fig. 3F). To determine whether these differences can mainly be attributed 
to differences in plasma content or phagocyte function, we used whole blood from which plasma was removed 
by centrifugation and replaced it with pooled plasma in which the concentrations of opsonizing antibodies and 
the complement activity are constant (see Material and Methods section for procedure). In this assay, killing of 
S. pneumoniae was more consistent (% survival 0.39–1.30), compared to survival in blood from the four sin-
gle donors (% survival 0.03–2.00) (Fig. 3F). These data indicate that mainly differences in plasma components 
(opsonizing antibodies and complement activity) between these four donors attribute to the inter-donor varia-
tion in whole blood killing capacity. This approach can also be used to determine vaccine-induced protection. 
Previously, Welsch et al. showed that supplementation of whole blood with 25% heat-inactivated post-vaccination 
serum increased killing of N. meningitidis compared to pre-immunization serum34. This approach enables com-
parison of whole blood killing of pathogens with different serum samples in combination with a single fresh 
blood donor.
Figure 3. Modulation of S. pneumoniae killing by modulating phagocytosis or complement activity. 
Bacterial survival in hirudin anticoagulated whole blood was determined after 2 hours incubation in the 
presence of (A) 10 μ g/mL CD11b blocking antibody (α -CD11b), 10 μ M actin polymerization inhibitor 
cytochalysin D (CytoD), (B) 10 μ M 4-hydroxitamoxifen (4-OHT) or (D) 100 μ g/mL human factor H (fH).  
(C) Bacterial survival in hirudin anticoagulated whole blood and blood with 50%, 25% and 10% active plasma 
was determined after 2 hours incubation (n = 4). (E) Bacterial survival of TIGR4 wild-type (WT) and TIGR4Δ 
pspC were determined after 2 h in hirudin anticoagulated whole blood. (F) Bacterial survival of TIGR4 was 
determined after 2 h in hirudin anticoagulated whole blood with or without plasma replacement. One-way 
analysis of variance (ANOVA) with Dunnett’s Multiple Comparison Test was used for statistical analysis (A,C). 
A one-tailed student t-test was used for statistical analysis (B,D–F). * p < 0.05.
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Contribution of C6 in opsonophagocytic-mediated killing of N. meningitidis. Patients with defi-
ciencies in the terminal complement components are more susceptible to invasive infections by N. meningitidis59. 
To mimic this in our whole blood killing assay, we replaced plasma with 10% C6-depleted serum and determined 
survival of N. meningitidis serogroup B strain H44/76 after 30 minutes. The presence of 10% heat-inactivated 
C6-depleted serum showed 9.1% survival (Fig. 4A), indicating that N. meningitidis serogroup B strain H44/76 
is killed by complement-independent mechanisms, which has been described in literature previously. For 
instance, N. meningitidis serogroup C was killed by antibody-dependent cell-mediated antibacterial activity60 
as well as opsonin-independent phagocytosis61. Opacity (Opa) proteins have been implicated to be important 
in opsonin-independent phagocytosis of N. meningitidis62,63 through neutrophil surface receptors CD66 and 
CR364,65, whereas macrophages bind unopsonized N. meningitidis almost exclusively via the class A macrophage 
scavenger receptor66. Although not investigated in detail, we show that N. meningitidis serogroup B strain H44/76 
is efficiently killed through complement-independent mechanism.
To study the contribution of complement in addition to complement-independent mechanisms, we used 10% 
C6-depleted serum in the whole blood killing assay. When 10% C6-depleted serum was used, survival was signif-
icantly lower (4.0%) compared to heat-inactivated serum (Fig. 4A). Since C6-depleted serum is not able to form a 
membrane attack complex, this increased killing is likely due to complement-dependent opsonophagocytosis. In 
order to restore terminal complex activity, we supplemented C6-depleted serum with C6 and observed a signifi-
cant increase in killing, implicating that formation of membrane attack complex, next to opsonin-dependent and 
opsonin-independent killing, contributed to overall clearance of N. meningitidis from whole blood.
Previously, we have described a patient with a novel heterozygous missense mutation in the C6 gene. Next to 
this novel heterozygous C6 mutation, a known heterozygous splice site variation was also identified, resulting in 
a C6 molecule that is 14% shorter due to a premature stop codon, but can still be build into the terminal comple-
ment complex, can kill bacteria, and is hemolytically active67,68. But, both mutations resulted in a lower (5%) C6 
protein level. Normal immunoglobulin levels (IgG/IgA/IgM/IgE) and other complement factors (C3, C4) were 
found. When 10% C6-deficient patient serum was used, survival was low (2.3%) (Fig. 4B), which was consistent 
with results obtained with C6-depleted serum. Survival was significantly lower when C6 was reconstituted (0.7%) 
(Fig. 4B), indicating that C6 supplementation increased bacterial killing in whole blood.
Altogether, these results with C6-depleted serum and C6-deficient patient serum obtained similar results; 
decreased killing as compared to C6-reconstituted serum, which is consistent with the clinical phenotype of these 
patients.
Monocytes and neutrophils contribute to opsonophagocytosis of S. pneumoniae. In order to 
address which cell type was predominantly responsible for opsonophagocytosis of S. pneumoniae in whole blood, 
we labelled S. pneumoniae with CFSE as previously described24. CFSE-labelled bacteria were added to whole 
blood in the absence or presence of cytochalysin D to block phagocytosis. Especially monocytes (74%) and neu-
trophils (72%) were found to bind and phagocytose S. pneumoniae, which was only 9% for lymphocytes (Fig. 5A). 
Cytochalysin D decreased S. pneumoniae association to monocytes, neutrophils and lymphocytes to 24%, 42% 
and 5%, respectively, indicating that half of the cells in the control condition actually phagocytosed S. pneumoniae, 
Figure 4. Contribution of C6 in opsonophagocytic-mediated killing of N. meningitidis. Bacterial survival 
of N. meningitidis strain H44/76 was determined after 30 minutes in hirudin anticoagulated whole blood with 
(A), 10% heat-inactivated serum, 10% C6-depleted serum, 10% C6-depleted serum supplemented with normal 
concentration C6 (see Material and Methods), (B) 10% C6-deficient patient serum, 10% C6-deficient patient 
serum supplemented with normal concentration C6. A one-tailed student t-test was used for statistical analysis. 
* p < 0.05, ** p < 0.01.
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whereas the other half of the CFSE-labelled bacteria were cell-associated. When the total percentage of S. pneu-
moniae association with cells was determined, most of them, 85%, were neutrophils, 10% monocytes and 5% 
lymphocytes (Fig. 5B), indicating that neutrophils are the most important cell type for opsonophagocytosis of 
S. pneumoniae in whole blood. These results are consistent with previous literature where phagocytosis experi-
ments showed efficient uptake of opsonized S. pneumoniae by both macrophages and neutrophils69–71. The impor-
tant role for neutrophils in opsonophagocytic killing and protection against pneumococcal disease is supported 
by in vivo models wherein neutrophils were depleted72,73.
Conclusion
The use of hirudin-anticoagulated whole blood enabled us to study the contribution of both bacterial and host 
factors in the killing of several pathogens, including S. pneumoniae, K. pneumoniae, S. aureus and H. influen-
zae. Complement activity preservation of hirudin was superior compared to lithium heparin, sodium heparin, 
EDTA or sodium citrate. Altogether, we describe a versatile assay to determine bacterial and host factors affecting 
opsonophagocytic killing of bacteria in hirudin-anticoagulated whole blood as a model for bacteremia.
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